Back to Search
Start Over
Clinicopathologic significance of excision repair cross-complementation 1 expression in patients treated with breast-conserving surgery and radiation therapy.
- Source :
-
International journal of radiation oncology, biology, physics [Int J Radiat Oncol Biol Phys] 2010 Mar 01; Vol. 76 (3), pp. 679-84. Date of Electronic Publication: 2009 May 21. - Publication Year :
- 2010
-
Abstract
- Purpose: The excision repair cross-complementation 1 (ERCC1) enzyme plays a rate-limiting role in the nucleotide excision repair pathway and is associated with resistance to platinum-based chemotherapy in cancers of the head and neck and the lung. The purpose of this study was to evaluate the clinicopathologic and prognostic significance of ERCC1 expression in a cohort of early-stage breast cancer patients treated with breast conservation therapy.<br />Methods and Materials: Paraffin specimens from 504 women with early-stage breast cancer treated with breast conservation therapy were constructed into tissue microarrays. The array was stained for estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) and ERCC1. This was then correlated with clinicopathologic factors and outcomes data.<br />Results: ERCC-1 expression was evaluable in 366 cases (72%). In this group, 32% and 38% of patients received adjuvant chemotherapy and hormonal therapy, respectively. Increased ERCC-1 expression was found to be correlated with ER positivity (p < 0.005), lower T stage (p < 0.017), nodal negativity (p < 0.013), age >50 (p < 0.006), reduced use of adjuvant chemotherapy (p < 0.02), and increased use of adjuvant hormonal therapy (p < 0.004). ERCC1 expression did not correlate with locoregional recurrence-free survival, distant metastasis-free survival, cause-specific survival, or overall survival. In patients who were both ERCC1-negative and -positive, the use of chemotherapy predicted for worse distant metastasis-free survival (p = 0.05 and p = 0.07, respectively) but not cause-specific survival or overall survival.<br />Conclusions: Although ERCC1 expression did not predict for outcome measures in this dataset, overexpression correlated with favorable prognostic factors such as ER positivity, lower T stage, nodal negativity, and age >50. To our knowledge, this is the first study investigating ERCC1 expression in patients receiving adjuvant radiation therapy for breast cancer.<br /> (Copyright (c) 2010 Elsevier Inc. All rights reserved.)
- Subjects :
- Adult
Age Factors
Aged
Aged, 80 and over
Breast Neoplasms pathology
Breast Neoplasms radiotherapy
Breast Neoplasms surgery
Chemotherapy, Adjuvant
Disease-Free Survival
ErbB Receptors metabolism
Female
Humans
Mastectomy, Segmental
Middle Aged
Receptors, Estrogen metabolism
Receptors, Progesterone metabolism
Tissue Array Analysis methods
Breast Neoplasms metabolism
DNA-Binding Proteins metabolism
Endonucleases metabolism
Neoplasm Proteins metabolism
Subjects
Details
- Language :
- English
- ISSN :
- 1879-355X
- Volume :
- 76
- Issue :
- 3
- Database :
- MEDLINE
- Journal :
- International journal of radiation oncology, biology, physics
- Publication Type :
- Academic Journal
- Accession number :
- 19464815
- Full Text :
- https://doi.org/10.1016/j.ijrobp.2009.02.050